TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression and/or Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide informed consent.~2. Not pregnant~3. Willing to participate in follow up as part of the study~4. Diagnosis of MDD and/or GAD by MINI~5. Current depressive episode with a MADRS score of ≥15 or Current GAD episode with GAD-7 score of ≥8.~6. Able to understand and comply with the requirements of the study~7. Able to provide stool and blood samples.~Exclusion Criteria:~1. History of chronic diarrhea~2. Need for regular use of agents that affect GI motility (narcotics such as codeine or morphine, agents such as loperamide or metoclopramide)~3. Colostomy~4. Elective surgery that will require preoperative antibiotics planned within 6 months of enrolment~5. Pregnant, breastfeeding, or planning to get pregnant in the next 6 months~6. Any condition for which, in the opinion of the investigator, the participant should be excluded from the study.~7. Current use of any antidepressant/antianxiety drug (eligible to participate after a 4-week washout period)~8. Use of any antibiotic drug in the past 4 weeks (may be eligible to participate after a 1-month washout period)~9. History of alcohol or substance dependence in the past 6 months~10. Daily use of probiotic product in the past 2 weeks (may be eligible to participate after a 2-week washout period)~11. Use of any type of laxative in the last 2 weeks.~12. Consumption of products fortified in probiotics~13. High suicidal risk, as measured by MADRS item 10 score more than 3 (or 4)~14. Current psychotic symptoms~15. Bipolar Depression~16. History of epilepsy or uncontrolled seizures~17. Immunodeficiency (immuno-compromised and immuno-suppressed participants; e.g. acquired immune deficiency syndrome \[AIDS\], lymphoma, participants undergoing long-term corticosteroid treatment, chemotherapy and allograft participants)~18. Unstable medical conditions or serious diseases/conditions (e.g. cancer, cardiovascular, renal, lung, diabetes, psychiatric illness, bleeding disorders, etc.)~19. The use of natural health products (Natural health products \[NHPs\]; e.g. St. John's Wort, passion flower, etc.) that affect depression~20. History of Electroconvulsive therapy (ECT)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Major Depression Disorder (Type: EXPERIMENTAL): MET-2 will be given to subjects with major depression disorder and its effect on mood will be measured
- Generalized Anxiety Disorder (Type: EXPERIMENTAL): MET-2 will be given to subjects with generalized anxiety disorder and its effect on mood will be measured

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects age 18 to 75 with a confirmed clinical diagnosis of plaque psoriasis and stable disease for at least 6 months prior to the study~* BSA involvement ≥ 20%~* PGA score of ≥ 3 at screening~* Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study~* Capable of giving written informed consent~Exclusion Criteria:~* Psoriasis other than plaque variant~* Any sign of infection of any of the psoriatic lesions~* Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with the interpretation of the results~* Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis~* Use of any prohibited medication within the indicated period before the first dose of study drug~* Pregnant females or lactating females~* The subject has received an investigational product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug~* Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix~* Previous known participation in a clinical study with tapinarof

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tapinarof (DMVT-505) cream, 1% (Type: EXPERIMENTAL): Tapinarof (DMVT-505) cream, 1% applied topically once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Pivotal Study of the Aptus Endovascular AAA Repair System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infrarenal AAA with a maximum diameter ≥ 4.5 cm.~* Infrarenal AAA with at least 12 mm length of non-aneurysmal proximal neck.~* Infrarenal AAA with a proximal neck internal diameter between 19-29 mm.~* Infrarenal AAA with an internal diameter at the aortic bifurcation ≥ 18 mm.~* Infrarenal AAA with an angle of ≤ 60° relative to the long axis of the aneurysm.~* Bilateral iliac artery distal fixation sites ≥ 10 mm in length.~* Bilateral iliac arteries with an internal diameter between 9 and 20 mm.~* Bilateral femoral/iliac arteries with morphology compatible with standard vascular access techniques and vessel size must accommodate a 16F (5.3 mm) or 18F (6.0 mm) delivery system.~Exclusion Criteria:~* Myocardial infarction within past 10 weeks.~* Active systemic infection.~* Ruptured or leaking AAA.~* Mycotic or inflammatory AAA.~* Genetic connective tissue disorders (e.g., Marfans or Ehlers-Danlos Syndromes).~* Concomitant TAA or thoracoabdominal aortic aneurysms.~* Requires emergent AAA surgery.~* Previous AAA repair.~* Patients with a body habitus that would prevent imaging required by the study.~* Patient has significant comorbid conditions that pose undue risk of general anesthesia or endovascular surgery.~* Patient requires additional planned major procedure at the time of AAA repair or within 30 days before or after AAA repair.~* Dialysis dependent renal failure or creatinine \> 2.5 mg/dL.~* Allergy to or intolerance of radiopaque contrast agents.~* Patients with a known sensitivity or allergy to implant materials.~* Patients who cannot discontinue oral anticoagulation or antiplatelet therapy at the time of the study procedure.~* Patients with history of bleeding diathesis or hypercoagulable condition.~* Patients with thrombus, calcification, and/or plaque ≥ 2mm in thickness and/or ≥ 50% (180°) continuous coverage of the vessel circumference in the intended seal zone.~* Patients with irregular shaped calcification and/or plaque that may compromise the fixation and sealing at the proximal or distal implantation sites.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AAA Repair System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a history of migraine with or without aura for 1 year or more with 2-8 moderate or severe migraine attacks per month~* Patient generally does not respond to treatment with sumatriptan~* Patient of reproductive potential agrees to remain abstinent or use one method of highly effective birth control (i.e. IUD, condoms, hormonal contraceptive, diaphragm, vasectomy) for the duration of the study~* Patient is able to complete paper diary~Exclusion Criteria:~* Patient is pregnant or breast feeding or excepts to become pregnant during the study~* Patient has history of mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours~* Patient has basilar or hemiplegic migraines~* Patient is unable to distinguish between migraine attacks from other types of headaches~* Patient has more than 15 headache-days per month~* Patient was greater than 50 years old at age of migraine onset~* Patient has failed to respond to 3 or more triptans~* Patient has a repeated history of failing to respond to or tolerate rizatriptan~* Patient uses opioids as primary migraine therapy~* Patient uses daily opioids~* Patient has a history of Cerebrovascular Accident (CVA) or other significant cardiovascular disease~* Patient has uncontrolled hypertension~* Patient has a history of neoplastic disease~* Patient is taking a serotonin reuptake inhibitor (SSRI or SNRI) where the dose has changed 3 months prior to screening~* Patient has a history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence A (Type: EXPERIMENTAL): Rizatriptan - Rizatriptan - Placebo
- Treatment Sequence B (Type: EXPERIMENTAL): Rizatriptan - Placebo - Rizatriptan
- Treatment Sequence C (Type: EXPERIMENTAL): Placebo - Rizatriptan - Rizatriptan
- Baseline Phase (Type: OTHER): Sumatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of Glycopyrrolate on Intubation With Rigid-videostylet (OptiScope®)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing elective laparoscopic cholecystectomy under general anesthesia~* aged from 19 to 65, adult patients~* american society of anesthesiologist physical status 1,2~* obtaining written informed consent~Exclusion Criteria:~* obese patients with body mass index above 30~* expected difficult intubation (ex. intraoral mass, history of former difficult intubation, limitation of mouth opening..)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Glycopyrrolate (Type: EXPERIMENTAL): Glycopyrrolate 0.005mg/kg is administered intramuscularly, one hour before the surgery.
- Control (Type: NO_INTERVENTION): No injection is conducted in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL~* Patient willing to be on a low-cholesterol diet~Exclusion Criteria:~* Pregnant or lactating women or intending to become pregnant~* Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet~* Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin~* Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Part 1 - Arm 1 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (ER)
- Part 1 -Arm 2 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin
- Part 1 - Arm 3 (Type: ACTIVE_COMPARATOR): Niacin (ER)
- Part 2 - Arm 1 (Type: ACTIVE_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (ER)
- Part 2 - Arm 2 (Type: PLACEBO_COMPARATOR): ezetimibe/simvastatin combination tablet + niacin (Pbo)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy volunteers, 18-50 years of age~* Seronegative for H5N1 (with antibody titres \<1:10 detected in HAI assay)~* Seronegative for H1N1 (with antibody titres ≤1:20 detected in HAI assay)~* Written informed consent to participate in this study~Exclusion Criteria:~* Acute febrile illness (\>37.0°C)~* Positive influenza immunoassay at baseline~* Signs of acute or chronic upper or lower respiratory tract illnesses (sneezing, cough, tonsillitis, otitis, etc.)~* History of severe atopy~* Influenza vaccination 2006/2007 and/or later~* Known increased tendency of nose bleeding~* Volunteers with clinically relevant abnormal paranasal anatomy~* Volunteers with clinically relevant abnormal laboratory values Females with positive urine pregnancy test prior to vaccination~* Simultaneous treatment with immunosuppressive drugs incl. corticosteroids (≥ 2 weeks) within 4 weeks prior to study medication application~* Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases~* History of leukaemia or cancer~* HIV or hepatitis B or C seropositivity~* Volunteers who had undergone rhino or sinus surgery or surgery of another traumatic injury of the nose within 30 days prior to application of study medication~* Volunteers who had received antiviral drugs, treatment with immunoglobulins or blood transfusions or an investigational drug within four weeks prior to study medication application~* Volunteers who had received anti-inflammatory drugs 2 days prior to study medication application~* Volunteers who were not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- GHB04L1 (Type: EXPERIMENTAL): GHB04L1 is administered as intranasal aerosol at a dose of 6.8 log10 or 7.5 log10 TCID50/dose/subject on day 1 and on day 29.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (buffer) is administered as intranasal aerosol on day 1 and on day 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Studies on Bile Acids in Barrett's Esophagus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have been scheduled for elective endoscopic examination at the Dallas VA Medical Center for the evaluation of GERD or Barrett's esophagus~Exclusion Criteria:~* Patients unwilling or unable to provide informed consent~* Patients with esophageal carcinomas~* Patients with esophageal varices~* Patients taking warfarin or clopidogrel~* Coagulopathy that precludes safe biopsy of the esophagus~* Comorbidity that precludes safe participation in the study~* Allergy to omeprazole or UDCA~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): All patients are treated with DCA and UDCA perfusion of the esophagus, one year apart, followed by 8 weeks of treatment with oral ursodeoxycholic acid 10 mg/kg qd. Then a final DCA perfusion of the esophagus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serologically Active, Clinically Stable Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets ACR criteria for SLE~* Inactive or stable in lupus activity~* History of positive dsDNA~* Current prednisone dose no more than 15 mg daily~Exclusion Criteria:~* Active infections~* Poorly controlled diabetes mellitus~* Pregnancy~* Uncontrolled hypertension

- Gender: FEMALE
- Minimum Age: 13 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone arm (Type: ACTIVE_COMPARATOR): Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.
- Placebo (Type: PLACEBO_COMPARATOR): Patients who remained clinically stable but showed serologic evidence of a lupus flare (elevation of both the anti-dsDNA level by 25% and the C3a level by 50% over the previous 1-2 monthly visits) were randomized receive either prednisone or placebo therapy at a dosage of 30 mg/day for 2 weeks, 20 mg/day for 1 week and 10 mg/day for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 18 to 55 years of age, inclusive.~* Body weight ranging from 50 to 100 kilograms (kg) and a body mass index (BMI) ≤ 30 kg/m2.~* Healthy as determined by unremarkable medical history, physical examination, vital signs, laboratory evaluations, electrocardiogram (ECG), and a 24-hour screening ECG telemetry.~* Willing to refrain from strenuous exercise or contact sports during the study.~* Female subjects must be surgically sterile or at least 2 years postmenopausal, or using an effective contraceptive method (intrauterine device, hormonal contraceptive, or double-barrier method).~Exclusion Criteria:~* Any clinically significant illness during the 30 days prior to randomization.~* Any history of allergy to buprenorphine, any excipient of BTDS, opioids, psychotropic or hypnotic drugs, and/or moxifloxacin or any member of the quinolone class of drugs.~* A clinically significant history of allergic reaction to wound dressings or bandages.~* Any medical or surgical conditions which might interfere with drug absorption (transdermal or gastrointestinal), distribution, metabolism, or excretion.~* Abnormalities on physical examination, vital signs, ECG, or clinical laboratory values, unless those abnormalities are judged to be clinically insignificant by the Investigator.~* Any cardiovascular disorders, including hypertension.~* Oxygen saturation (SpO2) ≤ 94% as measured by pulse oximetry.~* Any personal or family history of prolonged QT interval or disorders of cardiac rhythm.~* Abnormal cardiac condition denoted by any of the following:~* QT interval ≥ 450 milliseconds (msec).~* PR interval \> 240 msec or ≤ 110 msec.~* Evidence of second- or third-degree atrioventricular (AV) block.~* Pathological Q-waves (defined as Q-wave \> 40 msec or depth \> 0.5 mV).~* Evidence of ventricular preexcitation, complete left bundle branch block, right bundle branch block (RBBB), or incomplete RBBB.~* A resting heart rate outside the range of 50 to 85 beats per minute (bpm).~Other protocol-specific exclusion/inclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- BTDS (Type: EXPERIMENTAL): Buprenorphine transdermal patches 5, 10, 20, and 2 \* 20 mcg/h.
- Placebo TDS (Type: PLACEBO_COMPARATOR): Matching placebo transdermal patches 5, 10, 20 and 2 \* 20.
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin hydrochloride 400 mg tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who are ≥45 years of age and in generally stable health~* Participants who are in generally stable health and have a known diagnosis of Stasis Dermatitis or newly diagnosed Stasis Dermatitis~* Participants whose mental and physical status allows them to be able to mostly perform their activities of daily living with minimal assistance~Exclusion Criteria:~* Participants with clinically significant active or potentially recurrent dermatitis conditions and known genetic dermatological conditions that are not Stasis Dermatitis or overlap with Stasis Dermatitis~* Participants with active venous stasis ulceration on either lower extremity.~* Participants with current infection or suspected infection of any Stasis Dermatitis lesions~* Women of child bearing potential (WOCBP) are not eligible for this study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- crisaborole ointment (Type: EXPERIMENTAL): crisaborole ointment
- vehicle ointment (Type: SHAM_COMPARATOR): vehicle ointment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete